Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Past 7 days
    • Any time
    • Past hour
    • Past 24 hours
    • Past 30 days
The Lancet
13h

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

eBoehringer Ingelheim Pharma GmbH, Biberach an der Riß, Germany ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending now

Inflation rose in March
Ex-Baylor basketball star dies
Says he will not step down
Former NFL player shot in LA
$267M hospice fraud arrest
Severance terms revealed
Ordered to pay at least $53M
Pride flags to be removed
Proposes 82-cent stamp
To launch US pickup truck?
Revised press policy rejected
Approves new mining law
Sasse details cancer battle
Gets 3 to 9 years in prison
Bus plunges into a ravine
Lambrini Girls postpone tour
Former Russian official jailed
Vance warns Tehran
Loses appeal to dismiss case
5 charged w/ murder in blast
Sues Colorado over AI law
To close unionized MD store
Bissell recalls 1.7M cleaners
Gabbana exits chairman role
Announces Easter ceasefire
Withdraws drug application
CA deputy killed in shooting
Lufthansa cabin crew strike
Sued by African charity
Heads to Islamabad for talks
Embiid to undergo surgery
Judge denies Kalshi's request
Consumer sentiment drops
Meets Taiwan's leader
On poultry waste settlements
Released from hospital
Could miss start of playoffs
  • Privacy
  • Terms